First FDA-approved ALS drug in 22 years now available

Radicava (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS) from Japanese drugmaker Mitsubishi Tanabe Pharma (TYO: 4508), is now available in the USA.

It is the first US Food and Drug Administration-approved treatment in 22 years for ALS, an incurable neurodegenerative condition also known as Lou Gehrig’s disease, that affects the nerve cells in the brain and spinal cord.

Atsushi Fujimoto, president of Mitsubishi Tanabe Pharma America, said: “It gives me great joy that Radicava is now available in the USA.